



ASX ANNOUNCEMENT

12 March 2015

Cynata Therapeutics Commences Further Stage of Stem Cell Manufacturing Program

Melbourne, Australia: 12 March 2015: Stem cell and regenerative medicine company Cynata Therapeutics Ltd (ASX: CYP) announced today that it had commenced a further stage of the current mesenchymal stem cell (MSC) manufacturing program with Waisman Biomanufacturing in Madison, Wisconsin.

Dr Ross Macdonald, CEO and Managing Director stated, "Following the attainment of the major manufacturing milestone announced on 19 February 2015, Cynata is pleased to progress to a further stage of the contract manufacturing program with Waisman Biomanufacturing. The costs of this activity, along with planned product development of our Cymerus™ technology during the next 18-24 months, are adequately covered by our present cash balance so on that basis we have no current need to raise additional capital for some time. The Company does, however, intend to continue discussions in regard to potential technology licensing transactions, including up-front and milestone payments."

"Waisman will now move forward with the production of MSCs for further preclinical studies, and importantly, for our planned Phase 1 clinical trial in Graft versus Host Disease," said Dr Kilian Kelly, Cynata's Vice President of Product Development. "Our interaction with Waisman has been very productive and we look forward to the successful continuation of the program."

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA technology provides a consistent, reliable source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

CONTACTS: Dr. Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr. Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com
Kirin Smith, Chief Operations Officer, Investor Contact, + 1 646-863-6519, ksmith@pcgadvisory.com
Sean Leous, Chief Communications Officer, Media Contact, +1 646-863-8998, sleous@pcgadvisory.com